Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation.
- De Backer, Ole
- Pilgrim, Thomas
- Simonato, Matheus
- Mackensen, G Burkhard
- Fiorina, Claudia
- Veulemanns, Verena
- Cerillo, Alfredo
- Schofer, Joachim
- Amabile, Nicolas
- Achkouty, Guy
- Schäfer, Ulrich
- Deutsch, Marcus-André
- Sinning, Jan-Malte
- Rahman, Mohammed S
- Sawaya, Fadi J
- Hildick-Smith, David
- Hernandez, Jose Maria
- Kim, Won-Keun
- Lefevre, Thierry
- Seiffert, Moritz
- Bleiziffer, Sabine
- Petronio, Anna Sonia
- Van Mieghem, Nicolas
- Taramasso, Maurizio
- Søndergaard, Lars
- Windecker, Stephan
- Latib, Azeem
- Dvir, Danny
DOIAbstract
Patients with pure native aortic valve regurgitation (NAVR) and increased surgical risk are often denied surgery. This retrospective study aimed to evaluate the "off-label" use of transcatheter heart valves (THV) for the treatment of NAVR. A total of 254 high surgical risk patients with NAVR (age 74 ± 12 years, Society of Thoracic Surgeons risk score 6.6 ± 6.2%) underwent transcatheter aortic valve implantation (TAVI) with early generation (43%) or newer generation (57%) devices at 46 different sites. Device success was significantly higher in patients treated with newer as compared with early generation THV (82% vs 47%, p <0.001). The difference was driven by lower rates of device malpositioning (9% vs 33%) and aortic regurgitation (AR) ≥ ...
Add to ORKG